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Abstract
Background: Allergic Contact Dermatitis (ACD) is regarded as a T-cell-mediated delayed-type
hypersensitivity reaction. We studied the kinetics of the expression of CS-1 fibronectin, thymus
and activation-regulated chemokine (CCL17/ TARC) and different chemokine receptors (CR) in
skin biopsies from individuals suffering from back problems, with the antigen responsible of their
contact dermatitis and an irrelevant antigen.
Methods: Samples were taken at 2, 10, and 48 hours for histological and immunohistochemical
studies using monoclonal antibodies against human CS-1 fibronectin, CCL17, CD3, CD68, CD49d,
CXCR3, CCR5, and CCR3.
Results: At positive antigen stimulated sites there was an early expression of CS-1 fibronectin (2
hours), followed by CCL17 and a later accumulation of alplha4/beta1+ (CD49d), CD3+, CD68+,
CXCR3+ and CCR5+ mononuclear cells. At 48 hours, approximately 59 % of infiltrating cells were
CXCR3+, 42% CCR5+, and only 14 % CCR3+.
Conclusions: These results showed for the first time a very early expression of CS-1 fibronectin
which preceded production of CCL17 in blood endothelial cells (BCEs) from patients' skin with
ACD. The role of these molecules in recruitment of monocytes and effector T cells in ACD is
discussed.
Background
Allergic contact dermatitis (ACD) is one of the most com-
mon inflammatory diseases of the skin regarded as a pro-
totype of T-cell-mediated delayed-type hypersensitivity
reaction with a sensitization phase, generally asympto-
matic, an effector and resolution phases [1]. Its develop-
ment increases with age, the distribution in the
population is rather heterogeneous, its incidence and
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prevalence in children and adolescents is largely un-
known, and its socioeconomic impact as an acquired, job-
related disease is enormous [2,3]. The clinical spectrum
and diagnostic tools of the contact hypersensitivity reac-
tion has been reviewed elsewhere [4–6].
Haptens and epidermal cytokines activate Langerhans
cells (LCs) triggering a complex process that results in mi-
gration of these cells to the draining lymph nodes [7].
Moreover, mature dendritic cells (DCs) have a particular
kinetics of cytokine production that impact on priming of
different effector and memory T cells [8]. In addition re-
cent results have demonstrated that CD209-ICAM-2 inter-
action regulates chemokine-induced transmigration of
DCs across both resting and activated endothelium [9],
and that in vitro treatment of human transforming growth
factor-beta1-treated monocyte-derived DCs with haptens
can induce the phenotypic and functional changes similar
to LCs in the initiation phase of ACD [10].
The pathophysiological events in ACD are clearly mediat-
ed by skin-homing T cells and for the most common in-
ducer, Nickel (Ni), the molecular requirements for its
recognition by DCs and T lymphocytes have indicated
that uptake and processing mechanisms may not play a
major role [11] and specific combinations of TCR alpha-
and beta-chains are required excluding a superantigen-
like activation [12,13]. However, during the last two years
a large body of data has provided support for the idea that
ACD may not be a traditional type IV hypersensitivity. In
mice, neutrophil infiltration of hapten challenge sites is
required for elicitation of contact dermatitis and suggest
that neutrophils mediate recruitment of the specific CD8+
T cells that subsequently produce cytokines mediating the
hypersensitivity response [14,15]. Moreover, the co-ex-
pression of Th1 and Th2 cytokines during contact allergy
is an important feature of murine contact allergy in re-
sponsive mice [16].
The effector mechanisms are heterogeneous because ke-
ratinocytes can not only be target as thought in the pass by
CD4+ T cells [17] but also by multiple hapten-specific cy-
totoxic T lymphocytes responses. Tc1 and Tc2 displayed a
significant cytotoxic activity against resting sensitizer-
modified keratinocytes which is preferentially mediated
by perforin [18]. Recent studies have shown that Natural
Killer T cells, B-1 cells and TCRγδ T cells are involved in
contact sensitivity [19].
In spite of the surprising findings of preferential in vitro
synthesis of Th2 cytokines by peripheral blood mononu-
clear cells and T cell clones derived from individuals with
ACD [20,21], the majority of experiences to date reveals
that contact allergens stimulate the selective development
of type 1 immune responses and that keratinocyte apop-
tosis caused in different ways by skin-infiltrating T cells is
a key event in the pathogenesis of this disease [22–24].
Treatments at present time are avoidance of contact with
the sensitizer or the use of different drugs such as corticos-
teroids, cyclosporine and vitamin D3 [25], but the in-
crease knowledge of the immunopathogenic mechanisms
involved in ACD will help in the near future to develop
new therapeutic strategies to target key molecules in this
inflammatory process and thereby diminish the aberrant
immune response in a more effective way and with less
undesirable effects.
Some studies have shown that elevated expression of
TARC (CCL17), CTACK (CCL27), eotaxin (CCL11), eo-
taxin-2 (CCL24), and MCP-4 (CCL13) play an important
role in the recruitment of CCR4+ or CCR3+ inflammatory
cells into human skin in atopic inflammation [26–29].
More recently Goebeler et al have elegantly provided evi-
dences that migrating effector cells during elicitation of
ACD encounter multiple chemoattractant signals in a
complex spatial and temporal pattern [30].
CS-1 fibronectin, the connecting segment-1 motif present
in an alternatively spliced variant of fibronectin is an im-
portant ligand for α4β1 integrin [31]. This molecule has
already been shown to be selectively expressed in synovial
endothelium from biopsies with rheumatoid arthritis but
not in normal synovium [32]. Since there is not too much
information about the role of blood endothelial cells
(BECs) in early inflammation and subsequent accumula-
tion of mononuclear cells to challenge sites during ACD
we decided to studied the kinetics of the expression of CS-
1 fibronectin in comparison with TARC/CCL17 which
was until our results the earliest inflammatory marker of
inflamed BECs.
Methods
Human subjects
Subjects already diagnosed with ACD (n = 10) were re-
cruited from the Allergy Clinic at the Hospital Privado
(Córdoba, Argentina). Inclusion criteria were as follows:
1) age between 23–65 years, 2) history of ACD, 3) absence
of any other illness, and 4) positive skin patch tests at 48
hours to any antigen from the Patchkit Standard (FDA Al-
lergenic Ltda., Rio de Janeiro, Brazil). Patients gave in-
formed consent and the protocol was approved by the
Institutional Ethics Committee. Patients were not taking
oral or topical medication during at least one month be-
fore the beginning of this study.
Study design and processing specimens
Non irritating concentrations of antigens were applied un-
der 8-mm Finn chambers on Scanpor tape in the scapular
area at 5 cm of the spine. Using this method three cham-BMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/9
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bers containing the antigen responsible for the ACD (pos-
itive antigen) and one chamber with a non relevant
antigen (negative control) were used in each patient. Mac-
roscopic responses were measured at 2, 10, 48 hours by
evaluating skin erythema, papule and vesicle using the fol-
lowing arbitrary units (- = absent, + = mild, ++ = moder-
ate, +++ = intense).
A 3 mm disposable biopsy punch was used to take a biop-
sy form the center of each reaction at 2, 10, 48 hours after
using 1% lidocaine for local anesthesia. The control site
(negative antigen) was biopsied only at 48 hours. In this
way, each patient served as his/her own control. Tissue bi-
opsies were immediately fixed in 4% buffered formalin,
pH 7,4 and then were embedded in low-temperature par-
affin wax. Serial sections (6 µm) were cut from biopsies,
mounted on 0.1% poly-L-lysine-coated slides, dried over-
night at 37°C and stored until use.
Histology
One skin section from each biopsy was processed for his-
tologic conventional study and stained with hematoxilin/
eosin. The mononuclear cell infiltration in the dermis was
studied and classified as follow: scattered (+/-), mild (+),
moderate (++) and intense (+++).
Immunohistochemistry
Skin sections (6 µm) were dewaxed, rehydrated and then
boiled in Vector antigen unmasking solution (catalog #H-
3300, Vector Lab., Inc., Burlingame, CA, USA) in an 850-
W microwave oven for 10 minutes. Then the sections were
washed in Phosphate Buffer Saline (PBS – pH 7,6) during
20 minutes and the endogenous peroxidase activity in
skin was blocked with 3% hydrogen peroxide (Sigma
Chemical Co., Saint Louis, Missouri, USA) in PBS during
5 minutes and, subsequently washed thoroughly with
PBS. To block unspecific sites tissue samples were incubat-
ed with 3% bovine serum albumin (Sigma Chemical Co.,
Saint Louis, Missouri, USA) in PBS during 20 minutes, in-
cubated overnight at 4°C with anti-CD3 at 1:50, anti-
CD68 at 1:100 (Dako, Glostrup, Denmark) or anti-α4β1
1:6 (CD49d clone P4C2, CYTEL CORPORATION, San Di-
ego, CA, USA) or incubated for two hours at room temper-
ature with one of the following mAbs: mouse anti-human
CXCR3 (clone 1C6), anti-CCR5 (clone 2D7), anti-CCR3
(clone 7B11), anti-CCL17/TARC (clone 2D8) at 10 µg per
ml, or anti-CS1 fibronectin at 1:60 (clone 90.45, CYTEL
CORPORATION, San Diego, CA, USA). All mAbs against
chemokine and chemokine receptors were kindly provid-
ed by LeukoSite Inc., Cambridge, MA. Isotype-matched
immunoglobulins were used as negative controls. After
washing with PBS, the slides were incubated with the la-
belled streptavidin-biotin (LSAB) method according to
manufacturer's instruction (DAKO, Carpentería, CA,
USA). All incubations were performed at room tempera-
ture in a humid chamber, and the reaction cascade was
visualized by incubation with 3-amino-9-ethylcarbazole
(AEC) as substrate (DAKO, Carpentería, CA, USA). The
Table 1: Clinical and histological characteristics of ACD patients.
Patients Sex Age Skin Patch Test Reactivity Macroscopic response* Histologic grade**
Positive Antigen Negative Antigen Positive Antigen Negative Antigen Positive Antigen Negative Antigen
2 h 10 h 48 h 48 h 2 h 10 h 48 h 48 h
MO F 58 Neomicine Antraquinone - - +++ - +/- +/- +++ +/-
MR M 65 Thimerosal Antraquinone - - +++ - + ++ +++ +/-
AS F 46 Neomicine Antraquinone - - +++ - +/- + ++ +/-
ER M 49 p-phenylenediamine Antraquinone - - +++ - +/- ++ +++ +/-
IL F 49 Quarternium 15 Antraquinone - - +++ - +/- + + +/-
AC F 49 Quinolina mix Antraquinone - - +++ - +/- ++ +++ +/-
LG F 46 Balsamo Peru Antraquinone - - +++ - +/- + +++ +/-
MG F 29 Nickel Antraquinone - - +++ - +/- + ++ +/-
SA F 64 Irgasan Antraquinone - - +++ - +/- + ++ +/-
TV F 23 Nickel Antraquinone - - +++ - +/- + +++ +/-
* Skin erythema, papule and vesicle: – (absent); + (mild); ++ (moderate); +++ (intense). ** Mononuclear cell infiltration: +/- (scattered); + (mild); 
++ (moderate); +++ (intense). See Material and Methods.BMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/9
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slides were counterstained with hematoxilin and the sec-
tions were counted in duplicate on 14–17 adjacent fields
at 1000 × magnification blinded to the patient's clinical
status. The number of mononuclear cells expressing a par-
ticular antigen were informed per mm2, whereas the ex-
pression of CS-1 fibronectin and CCL17 on blood vessels
was measured using the following criteria (negative, low =
less than 40% of blood vessels, intermediate = between 40
and 70 % of blood vessels, and high = more than 70% of
blood vessels).
Statistical analysis
Variability of the parameters studied was analyzed with
Friedman's test, followed by two-by-two comparisons be-
tween time points using the Wilcoxon signed rank test.
Correlation coefficients were obtained by Spearman's
method with correction for tied values. For all tests, p <
0.05 was considered significant.
Results
All subjects exhibited a specific antigen-induced clinical
cutaneous response and a moderate to intense infiltration
of mononuclear cells distributed mainly around BECs at
48 hours. Although the macroscopic response to the pos-
itive antigens were negative at 10 hours, skin biopsies of
these sites showed a mild infiltration of mononuclear
cells. At 48 hours, the sham challenged sites showed cell
infiltrate comparable to the positive antigen sites at 2
hours (Table 1).
The histopathologic study of BECs from positive patch
tests at 48 hours showed a significant hypertrophy and
swelling compared to negative patch tests. This changes
started to appear at 2 hours where the vessels showed an
incipient but significant swelling (Figure 1).
Immunohistochemistry studies in all patients demon-
strated that CS-1 fibronectin expression started very early
Figure 1
Micrograph of skin biopsies after specific Ag challenge at 2 h (A), 10 h (B) and 48 h (C) and negative Ag site at 48 h (D) stained
with hematoxilin/eosin. Insert in upper right of each image show enlarged views of BECs from the same tissue section. Original
magnifications × 10 and × 40BMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/9
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(2 hours) in the lumen of endothelial cells in less than
40% of vessels and at 10 hours more than 70% of vessels
from positive patch tests' samples were positive for this
protein. By contrast, CCL17 expression was only seen after
10 hours in less than 40% of vessels and scattered kerati-
nocytes throughout the epidermis. The number of blood
vessels expressing both molecules decreased at 48 hours
and no immunoreactivity was found in biopsies from the
negative control challenge sites (Figure 2).
There were significant increases in α4β1+ (CD49d), CD3+
and CD68+ cells at positive antigen challenged sites at all
time points compared with negative antigen challenged
sites (p < 0.0001). The numbers of α4β1+, CD3+ and
CD68+ cells were maximal 48 hours after the specific an-
tigen challenge. T lymphocytes were observed mainly
around blood vessels whereas α4β1+ cells and CD68+
macrophages were distributed throughout the dermis and
the numbers of these infiltrating cells at 48 and 10 hours
were significantly higher than those at 10 and 2 hours, re-
spectively (p < 0.004) (Figure 3A).
As shown in figure 3B, significant differences (Ag- and 2-,
10- and 48-hours specific Ag challenge time points) were
observed for CCR5+ cells (p < 0.003), CXCR3+ cells (p <
0.003), and CCR3+ cells (p < 0.003). The numbers of
CXCR3+ and CCR5+ infiltrating cells at the specific anti-
gen challenge sites increased significantly between 2 and
10 hours (p < 0.03). This was not seen with CCR3+ cells.
Moreover, there was also significant differences between
for CXCR3+, CCR5+, and CCR3+ cells at 48 versus 10
hours (p < 0.007). Mononuclear cells expressing any of
the three CR keep raising until 48 hours and approximate-
ly 59 % were CXCR3+, 42 % were CCR5+ whereas only
14% were CCR3+. There was a significant correlation be-
tween the numbers of cells expressing CXCR3 and CCR5
protein at 10 and 48 hours (rs = 0.9; p = 0.0007).
Discussion and Conclusions
Efficient recruitment into inflamed skin requires excep-
tional adhesive interactions between mononuclear cells
and the inflamed endothelial cell lining of draining blood
vessels. In addition to the expression of E-selectin, CCL17,
CXCL16, CX3CL1, and increased numbers of integrin lig-
ands [33–35], we show here for the first time a very early
production of CS-1 fibronectin by activated endothelial
cells in patients with ACD. The expression of this mole-
cule may contribute to the enhanced stickiness of mono-
cytes and T cells expressing α4β1 integrin.
Within the extracellular matrix components fibronectin
play an important role in lymphocyte trafficking by in-
tegrins-ligands interaction. Activated lymphocytes express
α4β1 integrin which bind not only to VCAM-1 but to spe-
cific sites on the fibronectin molecule, the connecting seg-
ment-1 (CS-1) motif present in alternatively spliced
variants [31].
Enhanced adhesion of α4β1+ T lymphocytes to CS-1 fi-
bronectin in vitro has been shown in patients with vascu-
Figure 2
Micrograph of biopsies after specific Ag challenge at 2 h (A, E), 10 h (B, F) and 48 h (C, G), and negative Ag site at 48 h (D, H)
stained for CS-fibronectin (A-D) and CCL17 (E-H). Original magnifications × 40.BMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/9
Page 6 of 8
(page number not for citation purposes)
litis and rheumatoid arthritis and this molecule was
selectively expressed in synovial endothelium from biop-
sies with rheumatoid arthritis but not in normal synovi-
um [32,36].
CS-1 fibronectin and CCL17 are probably most important
in the rapid adhesion step, because of their presentation
by endothelial cells. Indeed they trigger rapid adhesion to
VCAM-1 and ICAM-1 of monocytes and T cells rolling on
E-selectin. Thus CS-1 fibronectin may work together with
CCL17 inducing adhesion of passing cutaneous α4β1+/
CCR4+ mononuclear cells under shear.
We also report here that CCL17 is also produced by scat-
tered keratinocytes in patients with ACD which since to be
similar to the finding of Vestergaard C et al in skin biop-
sies from patients with atopic dermatitis [29]. This chem-
okine may work together with CCL27 and MCP-1/CCL2
which are also produced by activated keratinocytes [30],
and may subsequently attract the adherent cells into the
epidermis of patients with ACD.
Since induction of CS-1 fibronectin production has also
been reported by us in lesional skin from patients with at-
opic dermatitis and irritative contact dermatitis [Martín
AP; Ortiz S; Cabalier MED; Frede S; Burgos E; Hliba E; Ser-
ra, HM. In press Journal Cutaneous Pathology], it is in-
ferred that this early inflammatory molecule is expressed
in skin's BEC upon different types of stimulus in a non an-
tigen-specific manner.
So a useful therapeutic strategy in dermatitis may be to
block α4β1 and CCR4 interactions with its ligands on in-
flamed endothelial cell surfaces, by specific antibodies or
antagonists. In this regard, CS-1 analogue peptide have
been efficiently used to diminish the efferent phases of
Th2 and Th1 mediated inflammatory responses in animal
models [[37,38], Serra et al, in preparation].
T lymphocytes with polarized cytokine production (Th1
and Th2) show a different distribution of inflammatory
CR, with CXCR3 and CCR5 transcripts markedly en-
hanced in Th1 cells and increased amounts of transcripts
for CCR3, CCR4 and CCR8 in Th2 cells [39]. Moreover a
large body of evidences indicate that the chemokine re-
ceptor CXCR3 and CCR5 are markers for T cells associated
with certain inflammatory reactions, particularly TH-1
type reactions [40,41].
In our kinetic study over a 48 hours course of provoked
human allergic contact dermatitis we found a gradual and
higher accumulation of CXCR3+ than CCR5+ cells which
was directly associated with CD3+ T cells. Flier J et al have
demonstrated differences in chemokine expression be-
tween ACD and ICD reactions being CXCL9, CXCL10 and
CXCL11 only detected in the allergic patch test lesions
[42]. Interestingly the proportion of cells in our allergic
patch test reactions expressing CCR5 was lower than those
that were CXCR3+, providing new evidences to the find-
ings of Yamamoto et al. who has demonstrated that
CXCR3 is the best marker for identification of circulating
Th1 effector population because Th1-type cytokine-pro-
ducing cells resided not only in CCR5-positive CD4+ T
cells but also in those that were CCR5-negative [43].
IL-17 is an important player of CD4+ T cell-mediated skin
inflammation in ACD with synergistic (ICAM-1, IL-8) or
antagonist (RANTES) effects on IFN-gamma-stimulated
Figure 3
Numbers of positive cells (mean +/- SEM) per square millim-
eter of α4β1+ (CD49d), CD3+ and CD68+ (A), CCR5+,
CXCR3+ and CCR4+ (B) infiltrating cells in antigen-chal-
lenged skin biopsies. Negative antigen-challenged sites (Ag-)
at 48 h were used as control. Significant differences (Ag- and
2-, 10- and 48-h specific Ag challenge time points; Friedman's
test) were observed for CD3+ T lymphocytes (p < 0.0001),
CD68+ macrophages (p < 0.0001), CXCR3+ cells (p <
0.003), CCR4+ cells (p < 0.003), and CCR3+ cells (p <
0.003).BMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/9
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keratinocyte activation [44]. Our results also confirmed
the finding of Albanesi et al. who have shown that the ma-
jority of infiltrating cells in ACD are recruited by CXCR3
agonistic chemokines released by keratinocytes activated
with IFN-gamma and TNF-alpha or IFN-gamma and IL-4
[45]. But here IL-4 exerts a proinflammatory function on
keratinocytes by potentiating IFN-gamma and TNF-alpha
induction of IP-10, Mig, and I-TAC, which in turn may de-
termine a prominent recruitment of CXCR3+ T lym-
phocytes at inflammatory reaction sites.
Our findings of a small number of CCR3+ cells infiltrating
the skin at 48 hours could be due to the present of T cells
releasing high levels of IL-10, low IFN-γ, and undetectable
IL-4 (Th IL-10) which have been reported to represent an
important mechanism for terminating Th1-mediated al-
lergic reactions and limiting excessive tissue damage. They
have a broad array of functional T1- and T2-associated
chemokine receptors, but also express high levels of CCR2
and CCR8 which allow resting as well as activated Th IL-10
cells to display a significant migratory capacity to CCL2
and CCL1 [46].
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